RxDoctor Payments Data

Netanel Benshalom, MD

Neurological Surgery · New York, NYNPI 1902234768

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (49.4%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. Longeviti Neuro Solutions Inc accounts for 96.1% of it on its own, with 5 other manufacturers making up the rest. 2025 is the largest year on record at $40,214, 2.0 times the $19,853 reported in 2022.

$91,651in general payments, 2019–2025

Across 79 payments — averaging $1160.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Longeviti Neuro Solutions Inc$88K
  • Medtronic$2K
  • Integra Lifesciences Corporation$2K
  • Stryker$155
  • Novocure Inc.$110
  • Meticuly Inc.$17
$40,460in research payments, 2019–2025

Across 2 payments — averaging $20,230 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Longeviti Neuro Solutions Inc$40K

What the payments were for

  • Royalty or licence$2,8223%
  • Consulting fees$45,23749%
  • Speaking & faculty fees$34,56638%
  • Travel & lodging$6,5147%
  • Food & beverage$2,5133%

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Longeviti Neuro Solutions Inc52$88,053
Medtronic18$1,684
Integra Lifesciences Corporation3$1,632
Stryker2$155
Novocure Inc.3$110
Meticuly Inc.1$17

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$91,651 in reported general payments places this provider in the 85th percentile of 446 neurological surgery providers in New York.

See all neurological surgery providers in New York →

Medicare billing

Part B allowed, 2024
$115,416
Medicare patients
56
Services billed
185

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other neurological surgery in New York

See the full list for New York →

Where these figures come from

Is this you, or does something look wrong? →